In the US, Metyrapone (metyrapone systemic) is a member of the following drug classes: adrenal corticosteroid inhibitors, in vivo diagnostic biologicals and is used to treat Diagnosis and Investigation.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Diagnostic agent: Pituitary function
- Metyraponum (Latin)
- Metyrapon (German)
- Métyrapone (French)
- Metirapona (Spanish)
- Metyrapone (OS: USAN, JAN, BAN)
- Methopyrapone (IS)
- Su 4885 (IS)
- Metyrapone (PH: BP 2016, JP XVI, USP 38)
Ceolia Pharma, Japan; HRA Pharma, Germany; LENIS, Slovenia; Medius, Switzerland
Cherubino, Malta; Healthcare Logistics, New Zealand; HRA, Netherlands; HRA Pharma UK and Ireland, United Kingdom; HRA Pharma UK and Ireland, Ireland; Laboratoire HRA Pharma, Israel; Laboratoire HRA Pharma, Poland; Novartis, Hong Kong; Novartis Pharmaceuticals, Australia
HRA Pharma France, France
|BAN||British Approved Name|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.